Abstract Number: 1668 • 2013 ACR/ARHP Annual Meeting
Does Fibrinogen Have a Role In The Assessment Of Patients With Giant Cell Arteritis?
Background/Purpose: Giant cell arteritis (GCA) in the most common systemic vasculitis in patients over 50 years of age. Considerable difficulties exist in the evaluation of…Abstract Number: 1669 • 2013 ACR/ARHP Annual Meeting
The Birmingham Vasculitis Activity Score As a Measure Of Disease Activity In Patients With Giant Cell Arteritis
Background/Purpose: To evaluate the performance of the Birmingham Vasculitis Activity Score (BVAS), a validated tool for assessment of vasculitis disease activity, in a cohort…Abstract Number: 1670 • 2013 ACR/ARHP Annual Meeting
Large Vessel Vasculitis: Estimating Disease Activity In Patients With Inflammatory Thoracic Aortic Aneurysms
Background/Purpose: Thoracic aortic aneurysms due to large vessel vasculitis may be a sign of ongoing inflammation or the sequelae of previous damage to the arterial…Abstract Number: 1671 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Risk At Incidence Of Giant Cell Arteritis: A Population Based Retrospective Cohort Study
Background/Purpose: Many systemic inflammatory rheumatic conditions are associated with increased cardiovascular (CV) risk. We aimed at assessing the CV risk at incidence of giant cell…Abstract Number: 1672 • 2013 ACR/ARHP Annual Meeting
Serious Cardiovascular Events Risk Factors In Giant Cell Arteritis. A Population-Based Study In The French Apogee Cohort
Background/Purpose: No population-based study has assessed serious cardiovascular events (sCVE) risk factors in Giant Cell Arteritis (GCA). The aim of our study was to identify…Abstract Number: 1673 • 2013 ACR/ARHP Annual Meeting
Risk Of Myocardial Infarction In Patients With Giant Cell Arteritis: A Population-Based Study
Background/Purpose: Involvement of large arteries leading to stenosis is well-documented in giant cell arteritis (GCA), but limited data are available on the risk of coronary…Abstract Number: 1674 • 2013 ACR/ARHP Annual Meeting
Acute Coronary Syndromes In Patients With Giant Cell Arteritis: A Population Based Retrospective Cohort Study
Background/Purpose: Acute coronary syndrome (ACS) is one of the leading causes of death in the general population. We aimed at assessing the occurrence of ACS…Abstract Number: 1675 • 2013 ACR/ARHP Annual Meeting
Infections Requiring Or Acquired During Hospitalizations In Patients With Giant Cell Arteritis – a Population Based Retrospective Cohort Study
Background/Purpose: There is a general impression that the patients with giant cell arteritis (GCA) on glucocorticoid therapy are at higher risk for infections. We aimed…Abstract Number: 1676 • 2013 ACR/ARHP Annual Meeting
Statins Do Not Influence Occurrence Or Prednisone Requirement Of Giant Cell Arteritis. A French Population-Based Cohort Study
Background/Purpose: Statins are widely prescribed to reduce the risk of cardiovascular ischemic events, but also present immunoregulatory effects promoting a shift from a TH-1 to…Abstract Number: 1677 • 2013 ACR/ARHP Annual Meeting
May Giant Cell Arteritis Be Characterized By Different Clinical Entity and Long-Term Outcome?
Background/Purpose: Giant cell arteritis (GCA) represents the most common primary vasculitis of the elderly, that affect large and medium-sized arterial vessels. Growing data shown that…Abstract Number: 1678 • 2013 ACR/ARHP Annual Meeting
How Similar Are Extracranial Giant Cell Arteritis and Takayasu Arteritis?
Background/Purpose: The clinical and radiographic features of giant cell arteritis (GCA) with extracranial (large-vessel) involvement can be similar to those of Takayasu arteritis (TAK)…Abstract Number: 1679 • 2013 ACR/ARHP Annual Meeting
Clinical Implications Of Antiphospholipid Antibodies In Takayasu’s Arteritis
Background/Purpose: Takayasu’s arteritis (TA) is a granulomatous inflammation of unknown origin involving the aorta and its major branches. Association and implication of antiphospholipid antibodies (aPL)…Abstract Number: 1680 • 2013 ACR/ARHP Annual Meeting
Predictivity Of Serum Biomarkers For Disease Activity In a Prospectively Followed-Up Takayasu Arteritis Cohort: Is Serum Amyloid A Protein Better Than Conventional Acute Phase Markers?
Background/Purpose: Takayasu arteritis (TA) is a chronic vasculitis with an indolent course. Reliable diagnostic and activity markers have not yet been demonstrated. We aimed to…Abstract Number: 1682 • 2013 ACR/ARHP Annual Meeting
Patients With TAKAYASU’S Arteritis Having Persistent ACUTE PHASE Response Usually Have An Increased MAJOR Vessel Uptake By 18F-FDG-PET/CT
Background/Purpose: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT) is a sensitive imaging tool for large-vessel vasculitis. Although not uniformly accepted, an increased uptake by 18F-FDG PET/CT…Abstract Number: 1683 • 2013 ACR/ARHP Annual Meeting
High Prevalence Of Metabolic Syndrome In Takayasu Arteritis: An Increased Cardiovascular Risk and Lower Adiponectin Serum Levels
Background/Purpose: The prevalence of Metabolic Syndrome (MetS) tends to be high among rheumatic patients, and cardiovascular disease is the leading cause of death in these…